Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
This still represents meaningful improvement for many individuals with CAI
First, PDEVs are naturally derived, highly biocompatible, and less likely to trigger immune responses [29,30,31]
Drivers of uptake include cost barriers of approved GLP-1RA therapies, limited PBS eligibility criteria, and the perception that grey-market alternatives offer equivalent therapeutic benefit at lower cost or access to more effective novel agents unavailable in Australia
Lancet Diabetes Endocrinol (2019) 7:35667
Smits MM, et al
US$ 23.14
US$ 26.39
